Cost-effectiveness inferences from bootstrap quadrant confidence levels: Three degrees of dominance

Journal of Biopharmaceutical Statistics

Volumn 15, Issue 3, 2005, Pages 419-436

  Obenchain, Robert L ^a   Robinson, Rebecca L ^a   Swindle, Ralph W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Bootstrap uncertainty distribution; Cost effectiveness; Depression; Duloxetine; Paroxetine; Resource utilization; Sensitivity analysis

Indexed keywords

DULOXETINE; PAROXETINE;

ARTICLE; CALCULATION; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; FOLLOW UP; HEALTH CARE POLICY; HUMAN; MAJOR DEPRESSION; OUTCOMES RESEARCH; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DRUG COSTS; DRUG THERAPY; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; THIOPHENES;

EID: 18744391951     PISSN: 10543406     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIP-200056525     Document Type: Article

References (25)

1. Black, W. C. (1990). The CE plane: A graphic representation of cost-effectiveness. Med. Decis. Making 10:212-214.
2. Briggs, A. H., Fenn, P. (1998). Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane (Student Corner). Health Econ. 7:723-740.
3. Briggs, A. H., Wonderling, D. E., Mooney, C. Z. (1997). Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Econ. 6:327-340.
4. Chaudhary, M. A., Stearns, S. C. (1996). Estimating confidence intervals for cost-effectiveness ratios: An example from a randomized trial. Stat. Med. 15:1447-1458.
5. Cook, J. R., Heyse, J. F. (2000). Use of an angular transformation for ratio estimation in cost-effectiveness analysis. Stat. Med. 19:2989-3003.
6. Copley-Merriman, C., Egbuonu-Davis, L., Kotsanos, J. G., Conforti, P., Franson, T., Gordon, G. (1992). Clinical economics: A method for prospective health resource data collection. Pharmacoeconomics 1(5):370-376.
7. Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallincrodt, C., Demitrack, M. A. (2004). Duloxetine in the treatment of depression - A double-blind, placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol. 24:389-399.
8. Hamilton, M. (1967). Development of a rating scale for primary depressive illness. British J. Soc. Clin. Psychol. 6:278-296.
9. Laird, N. M., Ware, J. H. (1982). Random-effects models for longitudinal data. Biometrics 38:963-974.
10. Laska, E. M., Meisner, M., Siegel, C., Stinnett, A. A. (1999). Ratio-based and net benefit-based approaches to health care resource allocation: Proofs of optimality and equivalence. Health Econ. 8:171-174.
11. Lave, J. R., Frank, R. G., Schulberg, H. C., Kamlet, M. S. (1998). Cost-effectiveness of treatments for major depression in primary care practice. Arch. Gen. Psychiatry 55(7):645-651.
12. Mallinckrodt, C. H., Clark, W. S., David, S. R. (2001a). Accounting for dropout bias using mixed-effects models. J. Biopharm. Stat. 11:1-13.
13. Mallinckrodt, C. H., Clark, W. S., David, S. R. (2001b). Type I error rates from mixed effects model repeated measures versus fixed effects ANOVA with missing values imputed via last observation carried forward. Drug Info. J. 35:1215-1225.
14. O'Brien, B. J., Drummond, M. F., Labelle, R. J., Willan, A. R. (1994). In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med. Care 30:231-243.
15. Obenchain, R. L. (1997). Issues and algorithms in cost-effectiveness inference. Biopharm. Rep. 5:1-7.
16. Obenchain, R. L. (1999). Resampling and multiplicity in cost-effectiveness inference. J. Biopharm. Stat. 9(4):563-582.
17. Obenchain, R. L. (2003). ICEplane: Microsoft Windows Software for Incremental Cost-Effectiveness Confidence Regions, Tolerance Regions, Acceptability and Net Benefit via Bootstrapping. Copyright © Pharmaceutical Research and Manufacturers of America (PhRMA). http://www.math.iupui.edu/ ~indyasa.
18. Obenchain, R. L., Melfi, C. A., Croghan, T. W., Buesching, D. P. (1997). Bootstrap analysis of cost-effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics 11(5):464-472.
19. Polsky, D., Glick, H., Willke, R., Shulman, K. (1997). Confidence intervals for cost effectiveness ratios: A comparison of four methods. Health Econ. 6:243-252.
20. Schoenbaum, M., Unutzer, J., Sherbourne, C., Duan, N., Rubenstein, L. V., Miranda, J., Meredith, L. S., Carney, M. F., Wells, K. (2001). Cost-effectiveness of practice-initiated quality improvement for depression: Results of a randomized controlled trial. JAMA 286(11):1325-1330.
21. Stinnett, A. A. (1996). Adjusting for bias in C/E ratio estimates. Health Econ. 5:470-472.
22. Stinnett, A. A., Mullahy, J. (1998). Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making (Special Issue on Pharmacoeconomics) 18:S68-S80.
23. Tambour, M., Zethraeus, N. (1998). Bootstrap confidence intervals for cost-effectiveness ratios: Some simulation results. Health Econ. 7:143-147.
24. Van Hout, B. A., Al, M. J., Gordon, G. S., Rutten, F. F. H. (1994). Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 3:309-319.
25. Willan, A. R., O'Brien, B. J. (1999). Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. Health Econ. 8:203-211.